Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.45 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.45 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16668510 | 1.00 | TSHR (0.58) | TSHRL3MBTL1LMNAALDH1A1PABPC1 | |
| SCHEMBL15994316 | 0.98 | TSHR (0.56) | TSHRL3MBTL1LMNAALDH1A1PABPC1 | |
| SCHEMBL17883542 | 0.98 | TSHR (0.56) | TSHRL3MBTL1LMNAALDH1A1PABPC1 | |
| SCHEMBL28301810 | 0.98 | TSHR (0.56) | TSHRL3MBTL1LMNAALDH1A1PABPC1 | |
| SCHEMBL15216418 | 0.98 | TSHR (0.56) | TSHRL3MBTL1LMNAALDH1A1PABPC1 | |
| SCHEMBL27274544 | 0.93 | TSHR (0.61) | TSHRL3MBTL1LMNAALDH1A1PABPC1 | |
| SCHEMBL4958389 | 0.93 | TSHR (0.61) | TSHRL3MBTL1LMNAALDH1A1PABPC1 | |
| SCHEMBL17883546 | 0.88 | ALDH1A1 (0.54) | TSHRL3MBTL1LMNAALDH1A1MAPT | |
| SCHEMBL17883545 | 0.88 | ALDH1A1 (0.54) | TSHRL3MBTL1LMNAALDH1A1MAPT | |
| SCHEMBL995832 | 0.84 | TSHR (0.61) | TSHRL3MBTL1LMNAALDH1A1PABPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| CN-109646424-B | Preparation method and application of phenolic compound | 四川好医生攀西药业有限责任公司 | 2022-06-14 | — | — | CN | disclosed |
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-05 | — | — | US | disclosed |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-22 | — | — | US | disclosed |
| US-9315486-B2 | Therapeutic cyclopentanols, compositions thereof, and methods for use thereof | ALLERGAN, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20150119454-A1 | THERAPEUTIC CYCLOPENTANOLS, COMPOSITIONS THEREOF, AND METHODS FOR USE THEREOF | ALLERGAN, INC. | 2015-04-30 | — | — | US | disclosed |
| US-8183246-B2 | Acyclically substituted furopyrimidine derivatives and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-05-22 | — | — | US | disclosed |
| US-8183246-B2 | Acyclically substituted furopyrimidine derivatives and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-05-22 | — | — | US | disclosed |
| US-20090318475-A1 | Novel, Acyclically Substituted Furopyrimidine Derivatives and Use Thereof | BAYER HEALTHCARE AG (DE) | 2009-12-24 | — | — | US | disclosed |
| US-20090318475-A1 | Novel, Acyclically Substituted Furopyrimidine Derivatives and Use Thereof | BAYER HEALTHCARE AG (DE) | 2009-12-24 | — | — | US | disclosed |
| US-20090318475-A1 | Novel, Acyclically Substituted Furopyrimidine Derivatives and Use Thereof | BAYER HEALTHCARE AG (DE) | 2009-12-24 | — | — | US | disclosed |
| WO-2008131858-A2 | USE OF ACYCLICALLY SUBSTITUTED FUROPYRIMIDINE DERIVATIVES FOR TREATING PULMONARY ARTERIAL HYPERTONIA | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2007079862-A1 | NOVEL, ACYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2007-07-19 | — | — | WO | disclosed |
| US-6815455-B1 | ANTIFOAM AGENTS OF MACROPHAGES; PREVENTING ARTERIOSCLEROSIS | FUJI PHOTO FILM CO., LTD. (JP) | 2004-11-09 | — | — | US | disclosed |
| EP-1197487-B1 | BENZIMIDAZOLE COMPOUNDS AND DRUGS CONTAINING THE SAME | FUJI PHOTO FILM CO LTD (JP) | 2004-01-14 | — | — | EP | disclosed |
| EP-1197487-A1 | BENZIMIDAZOLE COMPOUNDS AND DRUGS CONTAINING THE SAME | Fuji Photo Film Co., Ltd. (JP) | 2002-04-17 | — | — | EP | disclosed |
| US-4590291-A | Thrombin inhibitory new dihydroxybenzene ether derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 1986-05-20 | — | — | US | disclosed |
| EP-0068250-A1 | Dioxybenzene ether derivatives, pharmaceutical compositions containing them, process for the preparation thereof and their use | BAYER AG (DE) | 1983-01-05 | — | — | EP | disclosed |
| US-4259527-A | OXIDATION OF SECONDARY ALCOHOLS TO KETONES WITH HYDROGEN PEROXIDE | ALLIED CHEMICAL CORPORATION (US) | 1981-03-31 | — | — | US | disclosed |
| US-4171313-A | OF ALICYCLIC KETONES TO LACTONES, W-HYDROXY ACIDS AND ESTERS USING HYDROGEN PEROXIDE AS AN OXIDIZING AGENT | ALLIED CHEMICAL CORPORATION (US) | 1979-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119454-A1 | THERAPEUTIC CYCLOPENTANOLS, COMPOSITIONS THEREOF, AND METHODS FOR USE THEREOF | PTGIS, PDE3A, PTGIR | TSHR 4207/4885L3MBTL1 4806/4885LMNA 990/4885 |
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | TSHR 798/4885L3MBTL1 4270/4885LMNA 4193/4885 |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | TSHR 798/4885L3MBTL1 4270/4885LMNA 4193/4885 |
| US-20090318475-A1 | Novel, Acyclically Substituted Furopyrimidine Derivatives and Use Thereof | DPYD, PNPO, TPMT | TSHR 4264/4885L3MBTL1 2842/4885LMNA 2771/4885 |
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | TSHR 798/4885L3MBTL1 4270/4885LMNA 4193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.